(2)

Restructuring

During the second quarter of fiscal 2018, the Company began implementation of a plan to realign its business structure into two business units, Diagnostics and Life Science, supported by a global corporate team. As part of this plan, certain functions and locations within both business units have been streamlined, including: (i) the elimination of certain executive management and commercial sales positions; (ii) the closing of Life Science locations in Taunton, Massachusetts and Singapore, the operations of which were transferred to locations in Memphis, Tennessee and London, England, respectively; and (iii) the transfer of certain functions performed in the Billerica, Massachusetts Diagnostics facility to the corporate headquarters in Cincinnati, Ohio.

A summary of the restructuring costs recorded in fiscal 2018 is as follows:


	Fiscal 2018 Restructuring Costs
Severance, other termination benefits and related costs	$	5,012
Lease and other contract termination fees		353
Loss on fixed asset disposals and inventory scrap		225
Other		742

Total	$	6,332

The above table does not include $2,374 of CEO transition costs, which primarily represents the compensation and benefits for our previous Executive Chairman and CEO, Mr. John A. Kraeutler, throughout fiscal 2018, the period during which we also have the compensation and benefits our new CEO, Mr. Jack Kenny, who began employment at the beginning of fiscal 2018. These CEO transition costs and the restructuring costs set forth in the table above comprise the $8,706 of restructuring costs set forth in the accompanying Consolidated Statement of Operations.

At September 30, 2018, the accrued liability associated with the restructuring costs noted above consisted of the following:


	Balance as of
	September 30,
	2018
Severance, other termination benefits and related costs	$	987
Lease and other contract termination fees		33
Other		6

Total accrued liability balance	$	1,026